Table 2

Proportions of adherence to individual STARD items

OverallPost-STARD results only
STARD itemStudies evaluating item (n)Median of proportions (%)Range (%)Studies evaluating item (n)Median of proportions (%)Range (%)
25. Clinical applicability of findings149841–10059884–99
4. Participant recruitment168555–10079360–98
2. Research questions/aims148424–10058876–96
8. Technique of167331–9877440–97
 a. Index test59249–9548458–97
 b. Reference standard56313–8645523–72
15. Characteristics of study population167342–9077060–93
7. Reference standard and rationale167028–9877645–98
9. Units/cut-offs/categories for16700–9878363–85
 a. Index test58468–9549171–94
 b. Reference standard57355–7647556–80
3. Study population166823–9276321–88
6. Data collection166821–10078343–95
19. Cross tabulation of results15652–9966628–99
18. Distribution of severity of disease16620–9775211–98
21. Estimates of diagnostic accuracy155612–9765622–97
12. Methods for statistics used15498–9064911–90
14. Dates of study16476–7377342–81
1. Study identified as test accuracy study13408–10052418–99
5. Participant sampling164012–8976431–89
23. Estimates of variability of accuracy15370–1006390–100
17. Time interval between tests15340–7763825–74
11. Blinding of results of162914–5473316–55
 a. Index test54333–7245026–67
 b. Reference test52312–4842515–48
22. How uninterpretable results were handled15288–626258–57
10. Persons executing16262–737202–42
 a. Index test5337–464264–51
 b. Reference standard5200–354140–33
16. Eligible patients not undergoing either test16245–7875313–70
 a. Flow diagram1250–16480–22
13. Methods for test reproducibility for:15160–886180–88
 a. Index test42012–533356–48
 b. Reference standard470–12340–6
24. Estimates of test reproducibility, for:1580–96680–96
 a. Index test42013–383226–44
 b. Reference standard430–8300–6
20. Adverse events1270–336111–18